InterCure Ltd. (INCR)
NASDAQ: INCR · Real-Time Price · USD
1.510
+0.013 (0.85%)
Jul 16, 2025, 10:42 AM - Market open
Company Description
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally.
The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector.
The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
InterCure Ltd.
| Country | Israel |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 320 |
| CEO | Alexander Rabinovich |
Contact Details
Address: 85 Medinat ha-Yehudim Street Herzliya, 4676670 Israel | |
| Phone | 972 7 746 05012 |
| Website | intercure.co |
Stock Details
| Ticker Symbol | INCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| IPO Price | $0.00 |
| CIK Code | 0001857030 |
| CUSIP Number | M549GJ111 |
| ISIN Number | IL0011063760 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Rabinovich | Chief Executive Officer and Chairman |
| Amos Cohen | Chief Financial Officer |
| Einat Zehavi | Vice President of Sales |
| Itai Kabiljo | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 6-K | Report of foreign issuer |
| May 1, 2025 | 20-F | Annual and transition report of foreign private issuers |
| May 1, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Feb 13, 2025 | 6-K | Report of foreign issuer |
| Feb 3, 2025 | 6-K | Report of foreign issuer |
| Jan 31, 2025 | 6-K/A | Filing |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Dec 30, 2024 | 6-K | Report of foreign issuer |
| Dec 20, 2024 | 6-K | Report of foreign issuer |
| Dec 20, 2024 | 6-K | Report of foreign issuer |